Dedicated funds are available for a one-year grant through the generosity of The Charlie Landers Foundation to support Pediatric Ewing’s sarcoma research. This award is specifically designed to support young investigators and includes the potential for a second year of funding based on demonstrated progress and the joint approval of the Boards of Directors of The Charlie Landers Foundation.
.jpeg)
.jpeg)
.jpg)
.jpeg)
Innovative and transformative pre-clinical, translational, and clinical research, that has the potential to immediately impact the lives of Ewing sarcoma patients.
The Charlie Landers Foundation invites young investigators, including postdoctoral and clinical fellows, to apply.
Applicants must have their MD, PhD, or dual MD PhD.
At the time of the application due date, applicants must be within 5 years postfellowship with experience in translational research.
A minimum of 75% of the applicant’s time during the Young Investigator periodmust be allocated as protected time for all research activities.
The applicant must not currently hold an NIH independent (R or P Award) or individual training (F or K Award) grant. Institutional training grants (K12, T32) are permitted. Funding from other foundations is permitted, but those without funding will be prioritized.
A research mentor(s) must be identified and have a track record in pediatric oncology.
Funds must be granted to nonprofit institutions or organizations operating in the U.S.
Researchers need not be United States citizens.
The award amount is $50,000 for a period of one year.
An interim progress report will be required approximately six months following the start date of the award, and a final progress report will be due one month following the end date of the award.
If sufficient progress has been demonstrated, the awardee will have the option of a second year of funding with an additional $50,000 if approved by the medical advisory board.
Indirect costs are not permitted.
Budget items may include salary, fringe, travel, supplies and small pieces of equipment (less than $10,000).
All proposals must be combined into a single PDF and submitted via the form at the bottom of this page.
Application Deadline: 1/24/2025
Announcement of Recipient: 3/28/25
Start of Grant: July 1, 2025
Questions regarding applications should be directed to: lisa@thecharlielandersfoundation.org
Please include the following information using NIH grant guidelines:
Cover Page (1 page)
Title of Project
Institution
PI (s)
Contact information, Address, Key Contact Person
NIH Biographical Sketches for Key Study Personnel
Include Biosketch for PI(s), as well as trainees (residents, fellows) who will be directly involved in research project.
Lay and Scientific Abstract (1 page)
Lay summary of specific research project for which funds are sought (1/2 page)
Summary of specific research project for scientific audience (1/2 page)
Research Plan (4 pages)
Specific Aims
Significance and Impact
Approach
Anticipated Timeline for Research
Literature Cited
Career Development and Mentoring Plan (1 page)
Describe the mentor’s role in the experimental design and execution.
Describe detailed plan for career development including strategies for mentorship in pediatric oncology research, continued education, and future research/funding.
Mentor Letter of Recommendation
This letter is separate from the mentoring plan and should confirm the role and activities outlined in the mentoring plan.
Budget and Brief Justification (1 page)
See below for example template
Ok to use institutional template if preferred
Please list and/or describe any other sources of active and/or pending grant support
Collaborators and/or Consultants
Include any appropriate letters from individuals confirming their roles in the project.
The Charlie Landers Foundation is committed to improving the prognosis and quality of life for those affected by Ewing’s sarcoma by funding groundbreaking research, offering direct patient support, and raising awareness about this rare and underfunded form of pediatric cancer.
In our first year we allocated over $350k to four high impact grants in the ongoing search of a cure. Our next fundraising target is to raise $400,000 for our 2024 grant cycle.
